Pfizer Stock Nears Golden Cross, Signals Potential Upside With Strong Oncology Portfolio

Pfizer Inc (NYSE:PFE), one of the world's largest pharmaceutical firms, is on the verge of a bullish Golden Cross, a significant technical indicator suggesting potential upward momentum for the stock.

BenzingaJul 18 11:40 ET

Phase 3 VALOR Lyme Disease Trial: Valneva and Pfizer Announce Primary Vaccination Series Completion

New York, NY and Saint-Herblain (France), July 17, 2024 – Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that the participants of the Phase 3 trial “Vaccine Against Lyme for Outdoor Recreationists” (VALOR) have completed the primary vaccination series (three doses) of Lyme disease vaccine candidate VLA15. Participants will be monitored for the occurrence of Lyme disease cases until the end of the Lyme disease season in 2025.

valnevaJul 17 16:30 ET

Pfizer Options Spot-On: On July 17th, 236.13K Contracts Were Traded, With 2.92 Million Open Interest

On July 17th ET, $Pfizer(PFE.US)$ had active options trading, with a total trading volume of 236.13K options for the day, of which put options accounted for 21.65% of the total transactions, and

Moomoo NewsJul 17 16:30 ET

Express News | OPKO Health Inc: Also Permits OPKO to Maintain Full Benefit of $100 Mln of Remaining Potential Milestone Payments From Pfizer

ReutersJul 17 16:16 ET

Express News | OPKO Health Enters Into $250M Non-Dilutive Note Purchase Agreement With HealthCare Royalty Secured By Profit Share Payments From Pfizer For NGENLA

BenzingaJul 17 16:15 ET

Pfizer And Valneva Announce Primary Vaccination Series Completion In Phase 3 VALOR Lyme Disease Trial; Participants Completed Primary Vaccination Series (3 Doses) With VLA15

Participants completed primary vaccination series (3 doses) with VLA15Primary vaccination series to be followed by a booster approximately one year after completionNew York, NY and Saint-Herblain (

BenzingaJul 17 16:02 ET